ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Ann Thorac Surg 1996;62:1696-1697
© 1996 The Society of Thoracic Surgeons

Discussion

Discussion

The first 20% of the full text of this article appears below.

See also page 1691.

DR GEORGE M. PALATIANOS (Athens, Greece): We have been using leukocyte-filtered blood cardioplegia for the last 21/2 years. We have seen that the patients in whom we use this type of cardioplegia have less arrhythmogenic activity postoperatively, less reperfusion ventricular fibrillation, and a smaller need for antiarrhythmics. Also we have noticed less use of inotropic agents postoperatively. These are our clinical observations. I would like to ask you to comment on this protective effect of the leukocyte-depleted cardioplegic solution against the postoperative arrhythmogenic activity.

My . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.